Press Releases

CHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:  LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the William Blair 46 th Annual Growth Stock

CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:  LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at CDMO Live Europe.

-- Reaffirms 2026 Guidance -- -- Signed Three New Commercial Site Transfer Programs in First Quarter 2026 -- -- Cost Containment Initiatives Continue to Drive Down Expenses -- Conference Call Today at 8:00am ET CHASKA, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc.

Webcast Scheduled for Wednesday, May 6 at 8:00 a.m. Eastern CHASKA, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:  LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report

CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on April 20, 2026, Lifecore granted a restricted stock unit (“RSU”)

CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:  LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 12 th Annual American Biomanufacturing

CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on March 25, 2026, Lifecore granted a restricted stock unit (“RSU”)

-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive

-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months, Contributing to 2029 Revenue CAGR -- CHASKA, Minn., March 23, 2026 (GLOBE

-- Recorded  Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period -- -- Organizational Initiatives